FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892271477> ?p ?o ?g. }

• W2892271477 abstract "6623 Background: The French National Authority for Health (HAS) is responsible for health technology assessment (HTA), providing opinion on drugs for reimbursement and pricing purposes. For all indications with a positive opinion for reimbursement, HAS assesses the clinical added value (CAV) on a 5-point scale for pricing negotiations based on clinical data. A major to moderate CAV leads to the highest prices, a minor CAV leads to a higher price than the comparator, and no CAV leads to lower price than the cheapest comparator. Countries increasingly face the policy challenge of harnessing the benefits of cancer drugs while managing healthcare budgets. In this context, we aimed to analyze cancer drugs assessment by HAS. Methods: a retrospective and descriptive analysis comparing all new hematology/oncology cancer indications versus all others new indications assessed by HAS between 2010 and 2015 has been conducted. Results: 87 cancer indications (60 drugs) have been evaluated, representing 17% (87/510) of all new drugs indications assessed by HAS. Almost all cancer indications (92%) obtained a favorable opinion for reimbursement. Seven (8%) had an unfavorable opinion versus 20% in other therapeutic areas. However, 5 of these 7 indications were related to a drug included on the list of reimbursed drugs for another indication and consequently drugs are available. Overall, only 2 drugs were not reimbursed: nintedanib in non small cell lung cancer and tegafur/gimeracil/oteracil in gastric cancer (no impact on survival and lack of results transposability). Of the 80 indications with a favorable opinion, 20 had a major to moderate CAV (25%), 32 a minor CAV (40%) and 28 have no CAV (35%). Major to moderate CAV are mostly composed of hematology drugs (12, 60%). The proportion of major to moderate CAV assessment is higher in oncology than in other therapeutic areas (66% vs. 30%). Conclusions: France benefits from a universal healthcare system offering wide coverage and large access to drugs. Almost all of the new hematology/oncology cancer drugs assessed had a favorable opinion and are fully reimbursed (100%) by health insurance. A high proportion (66%) of CAV is recognized in oncology. Nevertheless, the over DRG list can inadvertently limit access to these new cancer drugs." @default.
• W2892271477 created "2018-09-27" @default.
• W2892271477 creator A5007034555 @default.
• W2892271477 creator A5012409743 @default.
• W2892271477 creator A5014849687 @default.
• W2892271477 creator A5016940868 @default.
• W2892271477 creator A5020414396 @default.
• W2892271477 creator A5073197753 @default.
• W2892271477 creator A5082190748 @default.
• W2892271477 creator A5082880665 @default.
• W2892271477 creator A5083401496 @default.
• W2892271477 date "2017-05-20" @default.
• W2892271477 modified "2023-09-23" @default.
• W2892271477 title "Access and price of cancer drugs: What is happening in France?" @default.
• W2892271477 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.6623" @default.
• W2892271477 hasPublicationYear "2017" @default.
• W2892271477 type Work @default.
• W2892271477 sameAs 2892271477 @default.
• W2892271477 citedByCount "0" @default.
• W2892271477 crossrefType "journal-article" @default.
• W2892271477 hasAuthorship W2892271477A5007034555 @default.
• W2892271477 hasAuthorship W2892271477A5012409743 @default.
• W2892271477 hasAuthorship W2892271477A5014849687 @default.
• W2892271477 hasAuthorship W2892271477A5016940868 @default.
• W2892271477 hasAuthorship W2892271477A5020414396 @default.
• W2892271477 hasAuthorship W2892271477A5073197753 @default.
• W2892271477 hasAuthorship W2892271477A5082190748 @default.
• W2892271477 hasAuthorship W2892271477A5082880665 @default.
• W2892271477 hasAuthorship W2892271477A5083401496 @default.
• W2892271477 hasConcept C121608353 @default.
• W2892271477 hasConcept C126322002 @default.
• W2892271477 hasConcept C142362112 @default.
• W2892271477 hasConcept C177713679 @default.
• W2892271477 hasConcept C2779527642 @default.
• W2892271477 hasConcept C3020340455 @default.
• W2892271477 hasConcept C52119013 @default.
• W2892271477 hasConcept C554144382 @default.
• W2892271477 hasConcept C71924100 @default.
• W2892271477 hasConceptScore W2892271477C121608353 @default.
• W2892271477 hasConceptScore W2892271477C126322002 @default.
• W2892271477 hasConceptScore W2892271477C142362112 @default.
• W2892271477 hasConceptScore W2892271477C177713679 @default.
• W2892271477 hasConceptScore W2892271477C2779527642 @default.
• W2892271477 hasConceptScore W2892271477C3020340455 @default.
• W2892271477 hasConceptScore W2892271477C52119013 @default.
• W2892271477 hasConceptScore W2892271477C554144382 @default.
• W2892271477 hasConceptScore W2892271477C71924100 @default.
• W2892271477 hasLocation W28922714771 @default.
• W2892271477 hasOpenAccess W2892271477 @default.
• W2892271477 hasPrimaryLocation W28922714771 @default.
• W2892271477 hasRelatedWork W1542733223 @default.
• W2892271477 hasRelatedWork W1972092775 @default.
• W2892271477 hasRelatedWork W1973275534 @default.
• W2892271477 hasRelatedWork W1981986007 @default.
• W2892271477 hasRelatedWork W2043816730 @default.
• W2892271477 hasRelatedWork W2062912128 @default.
• W2892271477 hasRelatedWork W2104388552 @default.
• W2892271477 hasRelatedWork W2131080517 @default.
• W2892271477 hasRelatedWork W2133598582 @default.
• W2892271477 hasRelatedWork W2140406691 @default.
• W2892271477 hasRelatedWork W2144532997 @default.
• W2892271477 hasRelatedWork W2158818165 @default.
• W2892271477 hasRelatedWork W2220044669 @default.
• W2892271477 hasRelatedWork W253549497 @default.
• W2892271477 hasRelatedWork W2554516665 @default.
• W2892271477 hasRelatedWork W2615724680 @default.
• W2892271477 hasRelatedWork W2775722023 @default.
• W2892271477 hasRelatedWork W2796572148 @default.
• W2892271477 hasRelatedWork W2948946518 @default.
• W2892271477 hasRelatedWork W2963502673 @default.
• W2892271477 isParatext "false" @default.
• W2892271477 isRetracted "false" @default.
• W2892271477 magId "2892271477" @default.
• W2892271477 workType "article" @default.